Lumida
/CGON
⌘K
CG Oncology Inc

CG Oncology Inc

CGON
$72.35USD↑+0.49%+0.35 today

MARKET CAP

6.4B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$72 – $75

52W RANGE

$33
$81

AI Summary

Stalk
Sell NowMedium

CGON is failing to sustain rallies above its declining 9-day and 20-day EMAs and has closed below the 50-day SMA, activating a Bearish Pivot Point in a Stage 3 distribution context. The medium-term bias shifts bearish as structural repair continues, and short-term timing favors selling on rallies into the EMA and 50 SMA zone. The long-term uptrend remains intact above the rising 200-day SMA, but reclaiming the EMAs and 50-day SMA would invalidate the current bearish posture.

  • ↑75% complete response rate in NMIBC trial signals clinical edge
  • ↑FY26 consensus revenue estimates up 35% to $4.47M
  • ↓Q2 2026 net loss $79.1M and R&D expenses of $54.7M
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

CG Oncology, Inc. (NASDAQ: CGON) is a biotechnology company focused on developing innovative therapies for cancer treatment, particularly targeting Non-Muscle Invasive Bladder Cancer (NMIBC). The company has made strides with its lead product, cretostimogene grenadenorepvec (cret), which demonstrates strong efficacy and safety profiles in clinical trials. Positioned within the oncology treatment market, CG Oncology is working towards establishing its place amidst increasing competition and evolving treatment paradigms, showcasing potential as a disruptor in bladder cancer therapies.

Bull says

  • ↑75% complete response rate in NMIBC trial signals clinical edge
  • ↑FY26 consensus revenue estimates up 35% to $4.47M
  • ↑$1B cash & equivalents funds operations through 2029
  • ↑High institutional ownership, led by Foresite Capital, signals strong backing
  • ↑Positive momentum and solid dividend yield factor may drive share gains
  • ↑Key clinical updates expected by end-2026 could catalyze valuation

Bear says

  • ↓Q2 2026 net loss $79.1M and R&D expenses of $54.7M
  • ↓Negative earnings yield and poor book-to-price highlight valuation risks
  • ↓High leverage raises financing risk amid tightening economic conditions
  • ↓Insider sales of $7.95M suggest management may lack confidence
  • ↓Weak profitability metrics underline challenges converting revenue to profit
  • ↓Commercialization risk remains high given biotech industry track record

Investment themes with CGON

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT
Demographics: Elderly Care↓ -0.50%

Services and products for aging population

UCB.BR · JNJ · AZN